Future therapeutic potential of SAP-1 in inflammatory bowel diseases

Takenori Kotani; Yoji Murata; Yasuyuki Saito; Takashi Matozaki

doi:10.1080/17474124.2016.1245144

Future therapeutic potential of SAP-1 in inflammatory bowel diseases

Expert Rev Gastroenterol Hepatol. 2016 Dec;10(12):1313-1315. doi: 10.1080/17474124.2016.1245144. Epub 2016 Oct 19.

Authors

Takenori Kotani¹, Yoji Murata¹, Yasuyuki Saito¹, Takashi Matozaki¹

Affiliation

¹ a Division of Molecular and Cellular Signaling, Department of Biochemistry and Molecular Biology , Kobe University Graduate School of Medicine , Kobe , Japan.

PMID: 27705005
DOI: 10.1080/17474124.2016.1245144

No abstract available

Keywords: CEACAM20; Protein tyrosine phosphatase; SAP-1; inflammatory bowel diseases; interleukin-10; intestinal epithelial cells; tyrosine phosphorylation.

Publication types

Editorial

MeSH terms

Animals
Cell Adhesion Molecules / metabolism
Epithelial Cells / drug effects*
Epithelial Cells / enzymology
Epithelial Cells / immunology
Gastrointestinal Agents / therapeutic use*
Humans
Immunity, Mucosal / drug effects*
Inflammatory Bowel Diseases / drug therapy*
Inflammatory Bowel Diseases / enzymology
Inflammatory Bowel Diseases / immunology
Intestinal Mucosa / drug effects*
Intestinal Mucosa / enzymology
Intestinal Mucosa / immunology
Molecular Targeted Therapy
Phosphorylation
Receptor-Like Protein Tyrosine Phosphatases, Class 3 / metabolism
Receptor-Like Protein Tyrosine Phosphatases, Class 3 / therapeutic use*
Signal Transduction / drug effects
Tyrosine

Substances

CEACAM20 protein, human
Cell Adhesion Molecules
Gastrointestinal Agents
Tyrosine
Receptor-Like Protein Tyrosine Phosphatases, Class 3